Karyopharm Therapeutics (FRA:25K) Accounts Payable & Accrued Expense : €55.1 Mil (As of Mar. 2024)

View and export this data going back to 2014. Start your Free Trial

What is Karyopharm Therapeutics Accounts Payable & Accrued Expense?

Karyopharm Therapeutics's quarterly accounts payable & accrued expense declined from Sep. 2023 (€53.1 Mil) to Dec. 2023 (€44.0 Mil) but then increased from Dec. 2023 (€44.0 Mil) to Mar. 2024 (€55.1 Mil).

Karyopharm Therapeutics's annual accounts payable & accrued expense declined from Dec. 2021 (€45.2 Mil) to Dec. 2022 (€39.2 Mil) but then increased from Dec. 2022 (€39.2 Mil) to Dec. 2023 (€44.0 Mil).

Karyopharm Therapeutics Accounts Payable & Accrued Expense Historical Data

The historical data trend for Karyopharm Therapeutics's Accounts Payable & Accrued Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Karyopharm Therapeutics Accounts Payable & Accrued Expense Chart

Karyopharm Therapeutics Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Accounts Payable & Accrued Expense

Get a 7-Day Free Trial

37.68

47.17

45.17

39.24

44.02

Karyopharm Therapeutics Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Accounts Payable & Accrued Expense	Get a 7-Day Free Trial															52.38	49.93	53.09	44.02	55.09

Karyopharm Therapeutics Accounts Payable & Accrued Expense Calculation

Accounts payable & accrued expense usually includes accounts payable, accrued compensation and related benefits, etc.

Accounts payable is money owed by a business to its suppliers shown as a liability on a company's balance sheet. It is distinct from notes payable liabilities, which are debts created by formal legal instrument documents.

It is part of the current portion of the liabilities (due within one year or within the normal operating cycle if longer) reflected on the balace sheet of the company. A higher Accounts Payable means lower Working Capital needed to operate the business.

Karyopharm Therapeutics (FRA:25K) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Karyopharm Therapeutics Inc (FRA:25K) » Definitions » Accounts Payable & Accrued Expense

Comparable Companies

Traded in Other Exchanges

KPTI:USA

Address

85 Wells Avenue, 2nd Floor, Newton, MA, USA, 02459

Website

https://www.karyopharm.com

Karyopharm Therapeutics Inc is a commercial-stage pharmaceutical company pioneering novel cancer therapies and dedicated to the discovery, development, and commercialization of drugs directed against nuclear export for the treatment of cancer and other diseases. XPOVIO (selinexor), is approved in the U.S. in multiple hematologic malignancy indications, including in combination with Velcade (bortezomib) and dexamethasone for the treatment of adult patients with multiple myeloma after at least one prior therapy, in combination with dexamethasone for the treatment of adult patients with heavily pretreated multiple myeloma and as a monotherapy for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma.

Karyopharm Therapeutics (FRA:25K) Headlines

No Headlines